dc.contributor.advisor | Jamiruddin, Mohd. Raeed | |
dc.contributor.author | Farzana, Atika | |
dc.date.accessioned | 2025-01-13T04:52:20Z | |
dc.date.available | 2025-01-13T04:52:20Z | |
dc.date.copyright | ©2023 | |
dc.date.issued | 2023-06 | |
dc.identifier.other | ID 18346056 | |
dc.identifier.uri | http://hdl.handle.net/10361/25134 | |
dc.description | This thesis is submitted in partial fulfillment of the requirements for the degree of Bachelor of Pharmacy, 2023. | en_US |
dc.description | Cataloged from PDF version of thesis. | |
dc.description | Includes bibliographical references (pages 22-33). | |
dc.description.abstract | Inspite of having no significant relationship with SARS CoV-2 infection, diabetes takes to disease severity which tends to mortality often. Patients having poor blood glucose management are susceptible to death more in COVID-19. The threshold of decreased death risk is between6 3.9 and 10.0 mmol/L. According to investigations, due to infections of COVID-19, diabetic patients had major problems and died. Diabetic patients have to experience significant COVID-19 problems including severe symptoms and consequences. So, scientists say that well-controlled diabetes can decrease getting ill from COVID-19. So, diabetic patients have to take foods, fruits and liquid, sweetened drink, honey in the time of increasing blood sugar and dropping blood sugar respectively. Anyway, for diabetic patients, insulin and metformin are commonly used to regulate blood glucose in COVID-19 individuals. Few applications of drugs are also used for diabetic patients which may affect the course of the COVID-19. GLP-1R agonists, SGLT2 inhibitors, DPP4 inhibitor and PPARs are included here. However, For the COVID-19 environment, diabetes treatment should be provided adequately. | en_US |
dc.description.statementofresponsibility | Atika Farzana | |
dc.format.extent | 43 pages | |
dc.language.iso | en | en_US |
dc.publisher | Brac University | en_US |
dc.rights | Brac University theses are protected by copyright. They may be viewed from this source for any purpose, but reproduction or distribution in any format is prohibited without written permission. | |
dc.subject | Diabetes mellitus | en_US |
dc.subject | COVID-19 | en_US |
dc.subject | SARS COV-19 | en_US |
dc.subject | SGLT2 inhibitors | en_US |
dc.subject | Glucagon-like peptide-1 | en_US |
dc.subject | Sodium-glucose Cotransporter -2 | en_US |
dc.subject | DPP4 | en_US |
dc.subject.lcsh | COVID-19 Pandemic, 2020---Influence--Health aspects. | |
dc.subject.lcsh | COVID-19 Pandemic, 2020---Physiological aspects. | |
dc.subject.lcsh | Diabetes. | |
dc.title | Regulating diabetes during COVID-19 – a review | en_US |
dc.type | Thesis | en_US |
dc.contributor.department | School of Pharmacy, Brac University | |
dc.description.degree | B. Pharmacy | |